These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2184002)

  • 1. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
    Lalonde RL; Tenero DM; Kazierad DJ
    Pharmacotherapy; 1990; 10(1):15-28. PubMed ID: 2179899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of clinical trials of dilevalol in essential hypertension.
    Glover DR; Tarbit WJ
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():49-53. PubMed ID: 2142508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranolol.
    Schoenberger JA; Wallin JD; Gorwit JI; Davidov ME; Michelson EL; Poland MP; Frishman WH
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):840-6. PubMed ID: 2686711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the efficacy and safety of dilevalol in the treatment of essential arterial hypertension].
    Bochicchio T; Pérez-Grovas HA; Carrizosa J; Herrera-Acosta J
    Arch Inst Cardiol Mex; 1989; 59(2):181-6. PubMed ID: 2569857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity.
    Wallin JD; Frishman WH
    J Clin Pharmacol; 1989 Dec; 29(12):1057-68. PubMed ID: 2693499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of antihypertensive action of dilevalol compared with that of "cardioselective" beta-blocking agents.
    Strom JA; Vidt DG; Bugni W; Atkins J; Fouad-Tarazi F; Cubbon J; Poland MP
    Am J Cardiol; 1989 Jun; 63(19):25I-33I. PubMed ID: 2729125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism.
    Sybertz EJ; Watkins RW
    Am J Cardiol; 1989 Jun; 63(19):3I-6I. PubMed ID: 2567112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study.
    Soberman J; Greenberg S; Frishman W
    J Clin Hypertens; 1987 Sep; 3(3):271-7. PubMed ID: 3312501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.
    Walley T; Tsao Y; Scott A; Mackay E; Vandenburg M; Breckenridge A
    Br J Clin Pharmacol; 1993 Jun; 35(6):623-8. PubMed ID: 8329290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.
    Baba T; Murabayashi S; Aoyagi K; Ishizaki T
    Eur J Clin Pharmacol; 1988; 35(1):9-15. PubMed ID: 2905992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
    Goa KL; Benfield P; Sorkin EM
    Drugs; 1989 May; 37(5):583-627. PubMed ID: 2663413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of dilevalol on adrenoceptors.
    Louis WJ; Drummer OH; Tung LH
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S5-11. PubMed ID: 2464095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive activity and duration of action of dilevalol in hypertensive patients at rest and during exercise. A comparison with captopril.
    Fogari R; Poletti L; Tettamanti F; Cesana B; Savonitto S
    G Ital Cardiol; 1990 Apr; 20(4):309-15. PubMed ID: 2197158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dilevalol compared with propranolol and placebo for systemic hypertension.
    Schoenberger JA; Frishman WH; Wallin JD; Gorwit J; Davidov ME; Michelson EL; Bedsole GD; Cubbon J; Poland MP
    Am J Cardiol; 1989 Jun; 63(19):45I-49I. PubMed ID: 2658529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.